Keybank National Association OH grew its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 0.2% in the second quarter, according to its most recent filing with the SEC. The fund owned 1,663,106 shares of the company’s stock after acquiring an additional 3,915 shares during the quarter. Johnson & Johnson comprises approximately 1.2% of Keybank National Association OH’s holdings, making the stock its 14th largest holding. Keybank National Association OH owned 0.06% of Johnson & Johnson worth $275,277,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently modified their holdings of JNJ. Farmers & Merchants Investments Inc. lifted its position in Johnson & Johnson by 1.2% in the second quarter. Farmers & Merchants Investments Inc. now owns 164,235 shares of the company’s stock worth $27,184,000 after buying an additional 1,954 shares during the last quarter. FIDELIS iM LLC bought a new stake in Johnson & Johnson in the second quarter worth $207,000. Pursue Wealth Partners LLC bought a new stake in Johnson & Johnson in the second quarter worth $881,000. Choate Investment Advisors lifted its position in Johnson & Johnson by 16.6% in the second quarter. Choate Investment Advisors now owns 79,544 shares of the company’s stock worth $13,166,000 after buying an additional 11,330 shares during the last quarter. Finally, BDO Wealth Advisors LLC lifted its position in Johnson & Johnson by 3.5% in the second quarter. BDO Wealth Advisors LLC now owns 16,998 shares of the company’s stock worth $2,813,000 after buying an additional 576 shares during the last quarter. 68.40% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
A number of analysts recently issued reports on the company. HSBC began coverage on Johnson & Johnson in a research report on Wednesday, September 6th. They issued a “hold” rating and a $175.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Atlantic Securities increased their target price on Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research note on Friday, August 4th. Credit Suisse Group increased their target price on Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research note on Friday, July 21st. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $169.19.
Johnson & Johnson Stock Performance
Shares of Johnson & Johnson stock opened at $145.60 on Monday. The firm has a market cap of $378.41 billion, a P/E ratio of 10.81, a P/E/G ratio of 2.94 and a beta of 0.55. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a 12 month low of $144.95 and a 12 month high of $181.04. The stock’s fifty day moving average price is $158.90 and its 200-day moving average price is $161.94.
Johnson & Johnson Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 5th. Stockholders of record on Tuesday, November 21st will be paid a dividend of $1.19 per share. The ex-dividend date of this dividend is Monday, November 20th. This represents a $4.76 annualized dividend and a dividend yield of 3.27%. Johnson & Johnson’s dividend payout ratio is currently 35.34%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Further Reading
- Five stocks we like better than Johnson & Johnson
- What is the Dogs of the Dow Strategy? Overview and Examples
- Is domestic travel back on track? Check out these companies
- Bank Stocks – Best Bank Stocks to Invest In
- MarketBeat Week in Review – 10/23 – 10/27
- Golden Cross Stocks: Pattern, Examples and Charts
- Can casino stocks win big if economy slows?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
